L
As of the edition of 20 October 2026, L runs 6 drugs, 3 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
L was acquired in 2022.
The records place 2 company names in this family.
- Tetraphase Pharmaceuticals, Inc: acquired in 2020; successor La Jolla Pharmaceutical Company
- La Jolla Pharmaceutical Company: acquired in 2022
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Angiotensin ii | none listed | 2 |
| Eravacycline | Ends 2037 (patent) | 0 |
| Pectin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| AGTR1 Type-1 angiotensin II receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where L needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Pregnancy and women's health: 8 trials led
- Urinary and reproductive: 8 trials led
- Infections: 6 trials led